Search results for " malignancy"

showing 10 items of 32 documents

Fertility sparing treatments in endometrial cancer patients: the potential role of the new molecular classification

2021

Endometrial cancer is the most frequent gynecological malignancy, and, although epidemiologically it mainly affects advanced age women, it can also affect young patients who want children and who have not yet completed their procreative project. Fertility sparing treatments are the subject of many studies and research in continuous evolution, and represent a light of hope for young cancer patients who find themselves having to face an oncological path before fulfilling their desire for motherhood. The advances in molecular biology and the more precise clinical and prognostic classification of endometrial cancer based on the 2013 The Cancer Genome Atlas classification allow for the selection…

Oncologymedicine.medical_specialtyQH301-705.5obstetric outcomesReviewHysteroscopyCatalysisFertility sparing surgeryInorganic ChemistryMolecular classificationPrognostic classificationInternal medicineCancer genomeOutcome Assessment Health CaremedicineHumansmolecular biologyPhysical and Theoretical ChemistryBiology (General)QD1-999SpectroscopyPregnancybusiness.industryEndometrial cancerOrganic ChemistryFertility PreservationCancerGeneral Medicinemedicine.diseaseEndometrial cancer; Fertility sparing; Molecular biology; Obstetric outcomes; PregnancyCombined Modality Therapyfertility sparingEndometrial NeoplasmsComputer Science Applicationsendometrial cancer; molecular biology; fertility sparing; obstetric outcomes; pregnancyChemistryFertilityGynecological malignancyendometrial cancerFemalepregnancyProgestinsbusinessOrgan Sparing Treatments
researchProduct

5-Year Overall Survival and Progression-Free Survival in Multiple Myeloma by Line of Treatment from the French Hematologic Malignancy Registry

2016

Oncologymedicine.medical_specialtybusiness.industryHealth PolicyPublic Health Environmental and Occupational Healthmedicine.disease03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicineHematologic malignancymedicineOverall survivalProgression-free survivalLine (text file)businessIntensive care medicineMultiple myelomaValue in Health
researchProduct

Epithelial-myoepithelial carcinoma of the salivary gland--a low grade malignant neoplasm? Report of two cases and review of the literature.

1999

Summary Epithelial-myoepithelial carcinomas (EMC) are rare neoplasms of the salivary gland with an incidence of less than 1% arising predominantly in the parotid gland. Although they are thought to be of low grade malignancy, fatal courses are described. We report a case of EMC of the parotid gland in a 58-year-old woman with an unfavorable course of this disease in long term follow-up. The malignant potential of this tumor is discussed. In addition, we include another case of EMC of the submandibular gland.

Pathologymedicine.medical_specialtySalivary glandbusiness.industryCarcinomaCell BiologyMiddle Agedmedicine.diseasePrognosisSalivary Gland NeoplasmsSubmandibular glandEpithelial-myoepithelial carcinomaLow grade malignancyLow Grade Malignant NeoplasmPathology and Forensic MedicineParotid glandstomatognathic diseasesmedicine.anatomical_structurestomatognathic systemmedicineHumansFemalebusinessPathology, research and practice
researchProduct

Intrahepatic cholangiocarcinoma: Limitations for resectability, current surgical concepts and future perspectives.

2020

Intrahepatic cholangiocarcinoma (iCCA) is the second most common hepatic malignancy and its incidence has been shown to increase significantly during the past decades. Complete surgical resection is currently acknowledged as the only curative treatment option able to provide adequate long-term outcomes. We herein review technical, functional and oncologic limitations for resectability, discuss current surgical aspects as well as highlight the fields in which future research and practice should focus on in order to ameliorate long-term outcomes in patients with iCCA.

Surgical resectionmedicine.medical_specialty030230 surgeryResectionBile duct cancerCholangiocarcinomaNeoplasms Multiple Primary03 medical and health sciences0302 clinical medicinePostoperative ComplicationsmedicineHepatectomyHepatic InsufficiencyHumansIn patientNeoplasm InvasivenessIntensive care medicineIntrahepatic Cholangiocarcinomabusiness.industryMargins of ExcisionGeneral Medicinemedicine.diseaseHepatic malignancyNeoadjuvant TherapyLiver TransplantationBile Ducts IntrahepaticOncologyBile Duct NeoplasmsCurative treatment030220 oncology & carcinogenesisBlood VesselsLymph Node ExcisionSurgeryLaparoscopyNeoplasm Recurrence LocalbusinessEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Chronic myeloid leukemia as second malignancy; restrospective multicentric study

2009

chronic myeloid leukemia second malignancySettore MED/15 - Malattie Del Sangue
researchProduct

Chronic myeloid leukemia as second malignancy; a retrospective multicentrico study

2009

chronic myeloid leukemia secondary malignancySettore MED/15 - Malattie Del Sangue
researchProduct

Humoral immunotherapy of multiple myeloma: perspectives and perplexities

2010

IMPORTANCE OF THE FIELDS Multiple myeloma (MM) is a hematological malignancy still remaining incurable despite the various therapies available, mainly because of the high fraction of refractory/relapsing cases. Therefore, the development of novel therapeutic approaches is urgently needed to overcome conventional treatment resistance. AREAS COVERED IN THIS REVIEW: In the era of targeted therapies, treatments combining a high specificity for neoplastic cells and the capability to interfere with environmental signals should be regarded as the weapons of choice. Monoclonal antibody (mAb)-based humoral immunotherapy could satisfy both these requirements when applied to MM. Indeed, many of the mo…

medicine.drug_classmedicine.medical_treatmentClinical BiochemistryCD38Monoclonal antibodyAntigens NeoplasmDrug DiscoverymedicineAnimalsHumansMultiple myelomamultiple myeloma; immunotherapyPharmacologyCD40biologybusiness.industryConventional treatmentAntibodies MonoclonalImmunotherapymedicine.diseaseImmunity Humoralmultiple myelomamultiple myeloma humoral immunotherapyHematological malignancyImmunologyMolecular targetsbiology.proteinimmunotherapybusiness
researchProduct

Acquired haemophilia in cancer: A systematic and critical literature review

2017

Aim There is a paucity of data on the clinical presentation and management of cancer patients with acquired haemophilia (AH), we here report a systematic literature review on acquired haemophilia in the context of cancer. Methods Treatment outcomes of AH were defined as complete response (CR), partial response (PR) or no response (NR), based on inhibitor eradication, coagulation factor VIII levels and bleeding control. Reported deaths were either related to cancer or bleeding. Results Overall, 105 cases were collected and analyzed according to classification of cancer and efficacy of treatments for inhibitor and malignancy. The mean age was 68 years for both males (range 37-86 years) and fe…

medicine.medical_specialtyContext (language use)Antineoplastic AgentsFactor VIIa030204 cardiovascular system & hematologyMalignancyHemophilia AGastroenterology03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineNeoplasmsAcquired haemophiliamedicineHumanscancerhaematological malignancyGenetics (clinical)Blood Coagulation Factor Inhibitorstreatmentbusiness.industryIncidence (epidemiology)AutoantibodyCancerHematologyGeneral Medicinemedicine.diseasebleedingBlood Coagulation FactorsRecombinant ProteinsSurgeryinhibitordiagnosiSystematic reviewTreatment Outcome030220 oncology & carcinogenesisHematologic Neoplasmsacquired haemophilabusinessHaematological malignancy
researchProduct

Pediatric oncologic endosurgery.

2017

Despite increasing popularity of minimal-invasive techniques in the pediatric population, their use in diagnosis and management of pediatric malignancy is still debated. Moreover, there is limited evidence to clarify this controversy due to low incidence of each individual type of pediatric tumor, huge diversity of the disease entity, heterogeneity of surgical technique, and lack of well-designed studies on pediatric oncologic minimal-invasive surgery. However, a rapid development of medical instruments and technologies accelerated the current trend toward less invasive surgery, including oncologic endosurgery. The aim of this article is to review current literatures about the application o…

medicine.medical_specialtyDisease entitybusiness.industryThoracoscopyMedical instrumentsLess invasive surgeryPediatric TumorEndosurgeryGeneral Medicine03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisPediatric malignancySolid tumorsmedicine030211 gastroenterology & hepatologyLaparoscopyLimited evidenceIntensive care medicinebusinessReview ArticlesChildrenPediatric populationInternational journal of surgery. Oncology
researchProduct

Efficacy and Safety of Tinzaparin in CAT Patients with Hematological Malignancy

2021

Abstract Introduction In patients with hematological cancers, the high risk of bleeding raises serious concerns when anticoagulant therapy is initiated for treatment of acute venous thromboembolism (VTE). In the CATCH trial, we showed that tinzaparin is associated with a significantly lower risk of clinically relevant bleeding (CRB) and clinically relevant non-major bleeding (CRNMB) compared with warfarin therapy in patients with a solid tumor or hematological cancer. Hence, we performed a post-hoc analysis to assess the risk of recurrent VTE (rVTE) and bleeding in the hematological cancer patient subgroup. Risk factors associated with rVTE and bleeding were also explored. Methods CATCH (Cl…

medicine.medical_specialtyHematological malignancybusiness.industryInternal medicineImmunologyMedicineCell BiologyHematologyTinzaparinbusinessBiochemistryGastroenterologyBlood
researchProduct